A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults above.

Trial Information

Start DateJune 2021
End DateTBD
Trial DurationTBD
Number of Visits8 visits
Lead CRCAdam Pawluch

For additional information
on this trial contact: